An empirical investigation of time-varying cost-effectiveness across the product life cycle
- 1 May 2020
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 29 (5), 580-590
- https://doi.org/10.1002/hec.4004
Abstract
Cost-effectiveness is traditionally treated as a static estimate driven by clinical trial efficacy and drug price at launch. Prior studies suggest that cost-effectiveness varies over the drug's lifetime. We examined the impact of "learning by doing," one of the least studied drivers of changes in cost-effectiveness across the product life cycle. We combined time-series trends in effectiveness over time by cancer regimen using the Surveillance, Epidemiology, and End Results-Medicare database. We estimated the time-varying effects of treatments in colorectal and pancreatic cancer over their life cycle, including FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin) and gemcitabine, on survival of patients. Mean prices over time by strength and dosage form were calculated using historical wholesale acquisition costs. We found consistent downward trends in the mortality hazard ratios, which suggest that effectiveness improves over time. In the case of first-line FOLFOX for colorectal cancer, the implied incremental cost-effectiveness ratio based on the observational data fell from $610,000 per life year gained in 2004 to $27,000 per life year gained in 2011. Cost-effectiveness estimated at launch is unlikely to be representative of cost-effectiveness over the drug's lifetime. In the drugs studied, the impact of time-varying clinical effectiveness dominated the impact of changing prices overtime.Funding Information
- Pfizer
This publication has 26 references indexed in Scilit:
- Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTAInternational Journal of Technology Assessment in Health Care, 2009
- A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancerCancer, 2009
- Dynamic Cost-Effectiveness: A More Efficient Reimbursement CriterionForum for Health Economics and Policy, 2008
- The Triple Aim: Care, Health, And CostHealth Affairs, 2008
- Value based pricing for NHS drugs: an opportunity not to be missed?BMJ, 2008
- The Volume–Outcome Effect, Scale Economies, and Learning-by-DoingThe American Economic Review, 2005
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003
- HEALTH TECHNOLOGY ASSESSMENT IN EUROPEInternational Journal of Technology Assessment in Health Care, 2000
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989
- Learning by Doing and the Introduction of New GoodsJournal of Political Economy, 1988